EVEROLIMUS vs INLYTA

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated August 18, 2026·How we rate

Possible drug interaction. EVEROLIMUS and INLYTA are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	EVEROLIMUS	INLYTA
Rating	70/100	New
Pharmacy pays	~$229.16 /30	—
Type	RX	RX
Active ingredient	EVEROLIMUS	AXITINIB
Manufacturer	Biocon Pharma	Pf Prism Cv
Dosage forms	Tablet	Tablet
Drug class	Kinase Inhibitor	Kinase Inhibitor
Boxed warning	Boxed warning	None
Half-life	about 30 hours (mean terminal elimination half-life)	—
Treats	—	Renal Cell Carcinoma

everolimus inlyta

Rating

70/100

New

Pharmacy pays

~$229.16 /30

—

Type

Active ingredient

EVEROLIMUS

AXITINIB

Manufacturer

Biocon Pharma

Pf Prism Cv

Dosage forms

Tablet

Drug class

Kinase Inhibitor

Boxed warning

None

Half-life

about 30 hours (mean terminal elimination half-life)

—

Treats

—

Renal Cell Carcinoma

Frequently asked questions

What is the difference between Everolimus and Inlyta?

Everolimus contains Everolimus, while Inlyta contains Axitinib — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.